Skip to main content
NCBI home page
RSC Advances logoLink to RSC Advances
. 2018 Mar 16;8(19):10644–10653. doi: 10.1039/c8ra00531a

A correlation study of biological activity and molecular docking of Asp and Glu linked bis-hydrazones of quinazolinones†

H K Kumara 1, R Suhas 1, D M Suyoga Vardhan 1, M Shobha 1, D Channe Gowda 1,✉
PMCID: PMC9078910  PMID: 35540474

Abstract

The present investigation involves the synthesis and spectroscopic and biological activity studies of the bis-hydrazones of quinazolinones derived from aspartic acid and glutamic acid. The antioxidant activities of the compounds were evaluated using DPPH, DMPD and ABTS radical scavenging assays whose results revealed that the IC50 of compounds 6, 7, 11, 12, 20, 21, 25 and 26 was lower than those of the standard references. The anti-inflammatory activity was evaluated with a haemolysis assay using a human blood erythrocytes suspension and the results demonstrated that compounds 8, 9, 13, 14, 22, 23, 27 and 28 were excellent anti-inflammatory agents. In addition, the antibacterial and antifungal activities against various clinical pathogens of human origin revealed that compounds 7, 9, 12, 14, 21, 23, 26 and 28 possessed potent antimicrobial properties. Furthermore, to understand the correlation between biological activity and drug–receptor interaction, molecular docking was performed on the active sites of tyrosine kinase (PDB ID: 2HCK), cyclooxygenase-2 (PDB ID: 1CX2) and glucosamine-6-phosphate (GlcN-6-P) synthase (PDB ID: 2VF5) which showed good binding profiles with the targets that can potentially hold the title compounds. The correlation study revealed that compounds containing EDGs (–OH, –OCH3) were excellent antioxidants, compounds with EWGs (–Cl, –NO2) exhibited good anti-inflammatory activity and compounds bearing –OH and –NO2 groups were very good antimicrobials.

The present investigation involves the synthesis and spectroscopic and biological activity studies of the bis-hydrazones of quinazolinones derived from aspartic acid and glutamic acid. graphic file with name c8ra00531a-ga.jpg

1. Introduction

Computational biology and bioinformatics play a major role in designing drug molecules and have the potential to speed up the drug discovery process. Molecular docking of the drug molecule with the receptor gives important information about drug–receptor interactions and is commonly used to find out the binding orientation of drug candidates to their protein targets in order to predict the affinity and activity.1 Medicinal chemistry is a specialized science that has evolved to encompass a broad range of disciplines concerned with the identification, synthesis and development of drug-like compounds for therapeutic use. It needs a wide range of expertise, developed through years of training, dedication and learning from best practice in order to produce drugs that are good enough to enter clinical trials with patients.2

Quinazolinones and their derivatives are building blocks of approximately 150 naturally occurring alkaloids isolated from plants, animals and microorganisms. The quinazolinone nucleus has diverse pharmacological activities, including antimicrobial,3 anti-inflammatory,4 antimalarial,5 anticonvulsant,6 antihypertensive,7 anti-diabetic,8 PARP inhibitory9 and anticancer activity.10 On the other hand, hydrazones are present in many bioactive heterocyclic compounds and are of wide interest because of their diverse biological and clinical applications. Moreover, hydrazones of quinazolinone derivatives exhibited enhanced biological activity, viz. antimicrobial,11 anti-inflammatory,12 antiviral,13 analgesic14 and anticancer activity.15 The structures of the biologically active quinazolinone-hydrazones are shown in Fig. 1.

Fig. 1. The structures of the biologically active quinazolinone-hydrazones.

Fig. 1

Open in a new tab

Besides these, amino acids are endogenous substances which could be used for the modification of drug skeletons to promote the absorption of drugs.16 In addition, the toxicity of drugs also could be reduced via the introduction of amino acids.17 Conjugation of amino acids/peptides with heterocycles,18,19 especially with a quinazolinone moiety,20–22 enhances the overall therapeutic properties of the molecule. Motivated by the aforementioned literature and the recent encouraging results from our research group,23–25 we have directed systematic efforts towards the synthesis of new bis-hydrazones of Asp and Glu linked quinazolinone derivatives followed by the study of their antimicrobial, antioxidant and anti-inflammatory activity. In addition, the results obtained were correlated with molecular docking studies in order to obtain some information about the binding efficiency and target interactions. The above are all collectively presented in this communication.

2. Results and discussion

2.1. Chemistry

The synthesis of the desired compounds was achieved according to the steps illustrated in Scheme 1. 3-(4-Oxo-3,4-dihydroquinazolin-2-yl)propanoic acid (QZN 1) and 4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoic acid (QZN 2) were synthesized by literature known methods.26–28 Conjugation of QZN 1/QZN 2 with p-TsOH·NH2–Asp(OBzl)–OBzl/HCl·NH2–Glu(OCH3)–OCH3 was carried out using EDCI/HOBt as the coupling agent and NMM as the base to obtain 1, 2, 15 and 16. Next, these conjugates were refluxed with an excess of hydrazine hydrate to obtain the corresponding bis-hydrazides of the quinazolinones, 3, 4, 17 and 18. These bis-hydrazides were allowed to react with various substituted aldehydes to obtain the bis-hydrazones of the quinazolinone derivatives, 5–14 and 19–28. All the compounds were obtained in good yields. The structures of all the newly synthesized compounds were confirmed by IR, 1H-NMR, 13C-NMR and mass spectral analyses. The conjugation of the quinazolinones with the amino acids was confirmed by the appearance of an –NH peak at δ 8.54–8.15 and the absence of a COOH signal at δ 12.25 in the 1H NMR spectrum. In the IR spectra, bands appeared at 3310 cm−1 (–NH2) and 3217 cm−1 (–NH) and in the PMR spectra, peaks appeared at δ 4.12–3.26 (–NH2) and 9.11–8.88 (–NH) which indicated the conversion of an ester into a hydrazide. The formation of the hydrazones (–N Created by potrace 1.16, written by Peter Selinger 2001-2019 CH) was confirmed by the presence of an absorption band at 1612–1630 cm−1 and a peak at δ 8.62–8.30. The presence of all requisite peaks and absence of extraneous peaks in the PMR and CMR spectra confirm the structures. Furthermore, the mass values obtained were in good agreement with the structures assigned (spectral data are provided in the ESI†).

Scheme 1. Bis-hydrazones of quinazolinone derived from anionic amino acid linkers. Reagents and conditions: (i) NMM, EDCI/HOBt, 0 °C to rt, (ii) NH2NH2·H2O, ethanol, reflux, 16 h, (iii) R–CHO, EtOH, reflux, 7–8 h.

Scheme 1

Open in a new tab

2.2. Biology

2.2.1. Antioxidant activity

The in vitro antioxidant activity of the synthesized compounds was evaluated with DPPH,29 DMPD,30,31 and ABTS32 radical scavenging assays. The values were determined in terms of the IC50, the concentration at which 50% of the radicals were scavenged, and were calculated to evaluate the antioxidant activity. The IC50 values were compared with those of the standards: ascorbic acid (AA) and gallic acid (GA). The results are tabulated in Table 1.

Antioxidant activity and docking studies of the synthesized quinazolinone derivativesa.
Entry Antioxidant activity Molecular docking studies with 2HCK protein
DPPH, IC50 (μg mL−1) DMPD, IC50 (μg mL−1) ABTS, IC50 (μg mL−1) Docking score H-bond interactions with AAb residues π-cation interactions π–π stacking interactions
1 >300 280 ± 5.23 290 ± 3.26 −3.865 Arg 136 Arg 76 NF
2 260 ± 3.56 >300 >300 −4.047 NF NF NF
3 250 ± 2.21 240 ± 1.35 180 ± 1.65 −4.545 Ala 96 NF NF
4 190 ± 1.40 >300 240 ± 1.32 −4.606 Ala 96, Asn 46 NF NF
5 85 ± 0.95 100 ± 1.56 70 ± 1.45 −6.250 Asn 46 NF NF
6 50 ± 0.45 55 ± 0.56 45 ± 1.20 −7.770 Ala 96, Asn 46 NF NF
7 35 ± 0.65 40 ± 0.72 25 ± 0.95 −9.375 Asp 73, Asp 73, Asn 46 Arg 76 NF
8 120 ± 1.26 140 ± 2.36 150 ± 0.68 −5.066 Arg 76, Arg 136 NF NF
9 180 ± 0.65 160 ± 0.65 145 ± 1.98 −5.983 Arg 136 NF NF
10 70 ± 0.65 95 ± 1.67 100 ± 1.85 −6.193 NF NF NF
11 50 ± 1.01 55 ± 0.98 45 ± 0.89 −7.779 Arg 136 Arg 76 NF
12 25 ± 0.26 30 ± 0.65 40 ± 0.65 −9.007 Asp 73, Asp 73, Asn 46 NF Arg 136
13 150 ± 3.26 135 ± 1.69 160 ± 1.98 −5.390 Arg 136, Asn 46 NF NF
14 180 ± 2.10 170 ± 0.98 155 ± 1.69 −5.797 Arg 136, Asn 46 NF NF
15 260 ± 3.65 >300 285 ± 2.65 −3.865 Arg 136, Gly 77 NF NF
16 >300 260 ± 3.45 >300 −4.188 NF NF NF
17 240 ± 2.98 225 ± 1.65 250 ± 3.56 −4.582 Ala 96, Asn 46, Gly 117 NF NF
18 >300 245 ± 2.56 280 ± 2.45 −4.606 Ala 96, Gly 117 NF NF
19 95 ± 0.95 80 ± 1.20 75 ± 0.56 −6.149 Arg 136 NF NF
20 45 ± 0.88 55 ± 0.75 40 ± 0.45 −7.983 NF NF NF
21 30 ± 0.23 35 ± 0.98 35 ± 0.69 −9.256 Arg 136, Asp 49, Asp 49, Glu 42, Glu 42 Arg 76 Arg 76
22 150 ± 2.23 120 ± 2.45 135 ± 1.90 −5.416 Arg 136, Asn 46 NF NF
23 200 ± 2.48 220 ± 1.65 205 ± 1.98 −5.129 NF NF NF
24 75 ± 1.45 80 ± 1.70 100 ± 1.65 −6.132 Arg 136 NF NF
25 35 ± 0.68 45 ± 1.20 50 ± 1.95 −8.097 Glu 50 NF NF
26 25 ± 0.24 30 ± 0.50 45 ± 0.64 −9.510 Arg 136, Asp 73, Asp73, Glu 42 Arg 76 NF
27 135 ± 1.98 150 ± 2.25 160 ± 1.40 −5.309 Asn 46, Glu 117 NF NF
28 165 ± 0.65 140 ± 2.50 130 ± 2.60 −4.973 Arg 136 NF NF
AA 50 ± 1.33 55 ± 2.26 45 ± 1.65 −6.499 Asp 73, Val 71 NF NF
GA 60 ± 1.46 65 ± 1.26 50 ± 0.36 −6.397 Asp 73 NF NF
Open in a new tab
a

The values are the means of three determinations, the ranges of which are <5% of the mean in all cases.

b

Amino acid; NF: not formed, AA = ascorbic acid, GA = gallic acid.

Most of the synthesized compounds showed antioxidant properties in all three radical scavenging assays. The conjugations of the QZN moiety with Asp (1 and 2) and Glu (15 and 16) showed antioxidant properties at higher concentrations which is in accordance with our earlier observations.33 Conversion of the esters into hydrazides (3, 4, 17 and 18) slightly improved the antioxidant potential, which may be due to the radical scavenging ability of NH–NH2 groups.34 The enhanced activity of the resultant hydrazones could be due to the presence of groups on the phenyl ring. Those compounds that lack substituents on the phenyl ring (5, 10, 19 and 24) showed moderate antioxidant activity with IC50 values ranging from 70–100 μg mL−1. Compounds with electron donating substituents like –OH and –OCH3 on the phenyl ring (6, 7, 11, 12, 20, 21, 25 and 26) exhibited excellent radical scavenging activity with IC50 values ranging from 25–55 μg mL−1 in all three antioxidant assays and even better results compared to the standards AA (45–55 μg mL−1) and GA (50–65 μg mL−1). In addition, the presence of OH slightly improved the antioxidant activity compared to that with OCH3. In contrast, compounds with electron withdrawing groups like –Cl and –NO2 on the phenyl ring (8, 9, 13, 14, 22, 23, 27 and 28) showed the lowest antioxidant activity with IC50 values ranging from 120–220 μg mL−1. On the basis of the above observation, it may be stated that compounds containing EDGs are excellent antioxidants,35–37 whereas the presence of EWGs decreases the antioxidant potential of the synthesized analogues.22 With respect to the length of the alkyl chain in the QZNs, there was no significance for the antioxidant potential. Replacement of Asp with Glu makes the antioxidant activity even better.

2.2.2. Anti-inflammatory activity

The human erythrocyte suspension was used to evaluate the in vitro anti-inflammatory activity of the synthesized molecules by employing a literature known method.38 A substantial number of compounds exhibited excellent to moderate activity compared to the standards, indomethacin (IM) and ibuprofen (IP). The results of the IC50 measurements were determined and are tabulated in Table 2. The compounds with electron withdrawing groups (8, 9, 13, 14, 22, 23, 27 and 28) showed excellent activity with IC50 values of 45, 25, 50, 45, 50, 40, 45 and 35 μg mL−1, respectively, which are more potent than those of indomethacin (55 μg mL−1) and ibuprofen (50 μg mL−1). Besides this, compounds with electron donating substituents like OH and OCH3 (6, 7, 11, 12, 20, 21, 25 and 26) or without any substituents (5, 10, 19 and 24) showed moderate activity. This clearly indicates that the compounds with electron withdrawing groups (Cl, NO2) on the phenyl ring are better anti-inflammatory agents.39 Furthermore, NO2 which is a powerful EWG is better at enhancing the anti-inflammatory activity than Cl.

Anti-inflammatory activity and docking studies of the synthesized quinazolinone derivativesa.
Entry Anti-inflammatory activity, IC50 (μg mL−1) Molecular docking studies with 1CX2 protein
Docking score H-bond interactions with AAb residues Electrostatic forces of attraction π-cation interactions π–π stacking interactions
1 270 ± 4.25 −4.164 Lys 118 NF NF NF
2 >300 −4.199 Lys 118 NF NF Phe 30
3 225 ± 2.69 −3.905 Lys 118 NF NF NF
4 >300 −4.068 Lys 118 NF NF Phe 30
5 100 ± 2.60 −4.678 NF NF NF Phe 30, Phe 30
6 75 ± 1.50 −4.879 Asp, 87, Lys 118 NF NF NF
7 80 ± 2.06 −4.976 Ala 161, Asp 90, Asp 90, Asp 120, Asp 120, Lys 118 NF NF Phe 30
8 45 ± 0.25 −8.576 NF NF NF Phe 30
9 25 ± 0.56 −8.908 Cys 20, Lys 118, Lys 118 Asp 13, Asp 87, Lys 118, Lys 118 NF Tyr 34
10 120 ± 1.40 −4.810 Lys 118, Asp 87 NF NF Phe 30
11 80 ± 1.50 −4.759 NF NF NF NF
12 65 ± 1.60 −4.719 Ala 161, Asp 120, Asp 120, Glu 32, Glu 32, NF Lys 118 Phe 30
13 50 ± 2.95 −7.810 Asp 87 NF NF His 126, Phe 30
14 45 ± 1.28 −8.027 Asp 87, Cys 20, Lys 118, Ser 88 Asp 13, Asp 87, Asp 90, Lys 118 NF NF
15 270 ± 2.90 −3.799 Lys 118, Gly 17 NF NF NF
16 >300 −3.850 Lys 118 NF NF NF
17 240 ± 3.40 −4.116 Asp 120, Lys 118, Lys 162 NF Lys 118 NF
18 260 ± 2.75 −3.630 Asp 87, Lys 118, Thr 127 NF NF Phe 30
19 150 ± 2.35 −4.378 NF NF NF NF
20 80 ± 0.54 −4.646 NF NF Lys 118 Phe 30
21 95 ± 0.45 −4.506 Asp 87, Asp 87, Asp 124, Lys 118, Lys 162, Lys 162 NF NF NF
22 50 ± 1.20 −7.843 Asp 87 NF NF Phe 30
23 40 ± 0.64 −8.023 Asp 87, Asp 87, Lys 118 Asp 13, Lys 118, Lys 162 NF Phe 30
24 115 ± 0.75 −4.378 Asp 87 NF NF His 126
25 75 ± 0.80 −4.482 Asp 87 NF Lys 118 Phe 30
26 90 ± 2.20 −4.472 Asp 87, Asp 87, Asp 90, Ser 88 NF NF Phe 30
27 45 ± 0.90 −8.143 Asp 87, Lys 118 NF NF Phe 30
28 35 ± 0.64 −7.928 Asp 87 Tyr 34 Lys 118 Tyr 34
IM 55 ± 2.01 −5.074 NF NF Lys 118 Phe 30
IP 50 ± 1.26 - - - - -
Open in a new tab
a

The values are the means of three determinations, the ranges of which are <5% of the mean in all cases.

b

Amino acid; NF: not formed; ‘-’: no activity/not analyzed, IM = indomethacin, IP = ibuprofen.

2.2.3. Antimicrobial activity

The efficacy of the synthesized compounds as antimicrobials was tested in antibacterial40 studies against different strains of pathogen using both Gram negative bacteria, namely Escherichia coli (E. coli), and Gram positive bacteria, Staphylococcus aureus (S. aureus), and in antifungal41 studies against Fusarium moniliforme (F. moniliforme) and Aspergillus niger (A. niger). The results obtained as the zone of inhibition (mm) are presented in Table 3. Streptomycin (SM) and bavistin (BS) served as the standard drugs for the antibacterial and antifungal studies, respectively.

Antimicrobial activity and molecular docking studies of the synthesized analogues with 2VF5.
Entry Antibacterial activitya (mm) Antifungal activitya (mm) Molecular docking studies with 2VF5
Docking score Hydrogen bond interactions with amino acid residues *π-cation interactions/#electrostatic forces of attraction
E. coli S. aureus F. moniliforme A. niger
1 04 ± 0.21 02 ± 0.32 05 ± 0.12 02 ± 0.41 −6.150 Ala 602, Glu 488, Ser 401 *Lys 603
2 03 ± 0.38 NA 02 ± 0.35 NA −6.196 Glu 488, Gly 301, Ser 401 NF
3 09 ± 0.65 07 ± 0.65 06 ± 0.65 04 ± 0.68 −7.990 Ala 602, Lys 603, Ser 347, Gln 348, Gln 348, Ser 303, Leu 346, Cys 300 NF
4 07 ± 0.45 NA 05 ± 0.38 03 ± 0.12 −7.804 Thr 302, Ser 401, Leu 346, Cys 300, Gln 348, Thr 352, Ser 303, Ser 347 NF
5 14 ± 0.32 10 ± 0.52 11 ± 0.42 09 ± 0.25 −8.203 Ala 602, Val 399, Lys 603, Gln 348, Ser 401, Ser 347 NF
6 16 ± 0.54 14 ± 0.16 15 ± 0.14 18 ± 0.54 NF NF NF
7 28 ± 0.32 25 ± 0.25 26 ± 0.28 24 ± 0.32 −12.238 Asp 354, Asp 354, Glu 488, Ala 602, Ser 401, Gln 348, Ser 303, Gly 301, Thr 352 NF
8 18 ± 0.18 16 ± 0.45 17 ± 0.36 15 ± 0.65 −8.597 Glu 488 NF
9 21 ± 0.23 19 ± 0.32 23 ± 0.23 24 ± 0.23 −10.017 Asp 354, Ala 602, Ala 602 #Asp 354, #Asp 354
10 10 ± 0.56 09 ± 0.23 11 ± 0.65 12 ± 0.45 NF NF NF
11 16 ± 0.36 15 ± 0.55 17 ± 0.11 18 ± 0.78 NF NF NF
12 26 ± 0.65 24 ± 0.85 25 ± 0.45 27 ± 0.28 −10.553 Asp 354, Asp 354, Val 399, Cys 300, Ser 347, Ser 349, Ala 602, Asn 600 NF
13 18 ± 0.12 17 ± 0.35 19 ± 0.26 20 ± 0.45 NF NF NF
14 22 ± 0.26 20 ± 0.38 21 ± 0.65 22 ± 0.22 −9.835 Lys 603, Ser 303, Asp 354 #Asp 354, #Asp 354
15 02 ± 0.35 NA 05 ± 0.32 01 ± 0.18 −5.966 Ala 602, Ala 602, Val 605, Thr 352, Ser 347, Ser 349, Gln 348, Ser 303 NF
16 NA 01 ± 0.08 NA 04 ± 0.26 −5.816 Ala 602, Thr 302, Ser 349, Ser 347 NF
17 04 ± 0.21 03 ± 0.21 05 ± 0.33 08 ± 0.21 −7.199 Ala 602, Ala 602, Leu 346, Cys 300, Gln 348, Ser 347, Lys 603, Lys 603 NF
18 05 ± 0.65 NA 07 ± 0.29 NA −7.170 Ala 602, Ala 602, Cys 300, Ser 347, Ser 349, Gln 348, Ser 401, Ser 401, Ser 303 NF
19 14 ± 0.35 11 ± 0.65 13 ± 0.26 14 ± 0.29 −8.083 Gln 348, Val 399, Thr 302, Ala 602, Ser 401 NF
20 18 ± 0.16 16 ± 0.19 15 ± 0.32 16 ± 0.11 −8.317 Ala 602, Lys 603, Ser 303 NF
21 28 ± 0.22 26 ± 0.35 25 ± 0.24 24 ± 0.26 −9.339 Thr 352, Ser 303, Asn 600, Ala 602, Asn 305, Gly 301 NF
22 19 ± 0.32 20 ± 0.17 18 ± 0.35 17 ± 0.56 −8.432 Thr 352, Lys 603, Thr 302, Val 399, Ala 602 NF
23 22 ± 0.56 24 ± 0.29 21 ± 0.65 23 ± 0.36 −8.969 Thr 302, Gln 348, Ser 303, Ser 347, Thr 352 #Glu 488
24 13 ± 0.25 10 ± 0.56 15 ± 0.36 14 ± 0.33 NF NF NF
25 16 ± 0.32 17 ± 0.44 18 ± 0.14 15 ± 0.38 NF NF NF
26 26 ± 0.35 22 ± 0.23 24 ± 0.36 25 ± 0.36 −9.282 Asn 305, Thr 352, Gln 348 NF
27 19 ± 0.26 16 ± 0.66 19 ± 0.56 20 ± 0.11 NF NF NF
28 24 ± 0.12 23 ± 0.33 24 ± 0.45 22 ± 0.65 NF NF NF
SM 15 ± 0.36 13 ± 0.69 — — −9.517 Gly 301, Asp 354, Asp 354, Cys 300, Thr 302, Ala 602, Ala 602, Glu 488 #Glu 488
BS — — 14 ± 0.65 13 ± 0.36 NF NF NF
Open in a new tab
a

The values are the means of three determinations, the ranges of which are <5% of the mean in all cases, NF = not formed, SM = streptomycin, BS = bavistin.

Most of the synthesized compounds showed promising antimicrobial activity with few exceptions. The results of the antimicrobial studies showed that all the analogues exhibited the same trend for both antibacterial and antifungal activity. The quinazolinone–amino acid conjugates (1, 2, 15 and 16) exhibited a much smaller zone of inhibition. When C-terminal benzyl ester/methyl ester groups were converted into hydrazides (4, 5, 17 and 18), there was a slight enhancement in the activity. This may be due to the increase in the polarity of the compounds, which would help the molecule to penetrate more through the cell membrane of microbes and thereby inactivate them.20 There was a drastic enhancement in the activity when the hydrazides were converted into hydrazones and we observed that the nature of the substituents present on the phenyl ring affected the biological activity of the compounds to a greater extent.

Among the bis-hydrazones, the compounds with hydroxyl groups (7, 12, 21 and 26) and nitro groups (9, 14, 23 and 28) on the phenyl ring showed potent antimicrobial activity compared to the standard drugs. Compounds bearing methoxy (6, 11, 20 and 25) and chloro (8, 13, 22 and 27) groups showed moderate antibacterial properties. Those compounds (5, 10, 19 and 24) which did not have any substituents on the phenyl ring showed the lowest activity. Thus the order of activity based on the groups attached to the phenyl ring of hydrazone derivatives was found to be OH > NO2 > Cl > OCH3 > H. An increase in the alkyl chain length of quinazolinone caused a slight decrease in the antimicrobial activity which is in good agreement with our earlier report.20 Replacement of Asp with Glu resulted in a slight decrease in the antimicrobial properties which may be attributed to the increase in hydrophobicity caused by the longer carbon chain in Glu.

2.3. Molecular docking studies

The results of the molecular docking studies of the title compounds with respect to the antioxidant, anti-inflammatory and antimicrobial properties are presented below.

Molecular docking was performed on the active site of tyrosine kinase (PDB ID: 2HCK) with the synthesized ligands (1–28) in order to determine the possible binding interactions of highly potent molecules. Most of the compounds showed good docking scores and potent interactions with different amino acid residues and the results are tabulated in Table 1. Among the series of compounds, those possessing EDGs, especially hydroxyl groups (7, 12, 21 and 26), gave the highest docking scores. The binding interactions (2D and 3D) of 7, 12, 21 and 26 are displayed in Fig. 2. Compound 7 showed hydrogen bond interactions with Asp 73, Asp 73 and Asn 46 and π-cation interactions with Arg 76 and compound 12 showed hydrogen bond interactions with Asp 73, Asp 73, and Asn 46 and π–π stacking interactions with Arg 136. Compound 21 showed hydrogen bond interactions with Arg 136, Asp 49, Asp 49, Glu 42 and Glu 42 and π-cation and π–π stacking interactions with Arg 76 and compound 26 exhibited hydrogen bond interactions with Arg 136, Asp 73, Asp 73 and Glu 42 and π-cation interactions with Arg 76. These molecules showed the highest docking scores because of the involvement of hydroxyl groups on the phenyl ring in hydrogen bond interactions.

Fig. 2. 2D and 3D images of compounds 7, 12, 21 and 26 with 2HCK.

Fig. 2

Open in a new tab

To rationalize the anti-inflammatory potential of the synthesized compounds (1–28), we conducted docking studies on the crystal structure of cyclooxygenase-2 (PDB ID: 1CX2). Most of the compounds exhibited a good docking score and different kinds of interaction with amino acid residues and these are tabulated in Table 2. Analogues with EWGs, particularly with NO2 (9, 14, 23 and 28) on the phenyl ring, displayed good interactions with amino acid residues and had the highest docking scores. Molecular docking studies provided an interaction map of cyclooxygenase-2 with 9, 14, 23 and 28 and the results are presented in Fig. 3. Compound 9 showed hydrogen bond interactions with Cys 20, Lys 118 and Lys 118, electrostatic forces of attraction with Asp 13, Asp 87, Lys 118 and Lys 188 and π–π stacking interactions with Tyr 34; and compound 14 showed hydrogen bond interactions with Asp 87, Cys 20, Lys 118 and Ser 88 and electrostatic interactions with Asp 13, Asp 87, Asp 90, Lys 118 and Lys 118. Meanwhile, compound 23 displayed hydrogen bond interactions with Asp 87, Asp 87 and Lys 118, electrostatic interactions with Asp 13, Lys 118 and Lys 162 and π–π stacking interactions with Phe 30, whereas compound 28 showed hydrogen bond interactions with Asp 87, π-cation interactions with Lys 118 and Tyr 34 and π–π stacking interactions with Tyr 34. The NO2 groups present on the phenyl ring involved in electrostatic forces of attraction and π-cation interactions led to an enhanced docking score.

Fig. 3. 2D and 3D images of compounds 9, 14, 23 and 28 with 1CX2.

Fig. 3

Open in a new tab

In order to gain insight into the exact binding location of the ligands with the protein, all the synthesized molecules (1–28) including the standards were subjected to molecular docking with the active site of GlcN-6-P synthase (PDB ID: 2VF5). They showed good binding interactions with the surrounding amino acid residues. The docking score and the interacting amino acids are tabulated in Table 3. Most of the synthesized compounds exhibited well established bonds with one or more amino acids in the receptor active pocket of 2VF5 protein. The potential of the compounds as antimicrobial agents was determined based on the docking scores. The docking scores with 2VF5 protein ranged from −12.238 to −5.816 and the highest negative value indicates the best docked ligand to the targeted site. The 2D and 3D images of compounds 7, 9, 21 and 23 are shown in Fig. 4. Aspartic acid linked hydrazones (7) showed hydrogen bond interactions with Asp 354, Asp 354, Glu 488, Ala 602, Ser 401, Gln 348, Ser 303, Gly 301 and Thr 352 and compound 9 showed hydrogen bond interactions with Asp 354, Ala 602 and Ala 602 and electrostatic forces of interaction with Asp 354 and Asp 354. On the other hand, glutamic acid linked hydrazones (21) displayed hydrogen bond interactions with Thr 352, Ser 303, Asn 600, Ala 602, Asn 305 and Gly 301 and compound 23 showed hydrogen bond interactions with Thr 302, Gln 348, Ser 303, Ser 347 and Thr 352 and electrostatic forces of interaction with Glu 488. The involvement of the hydroxyl groups in hydrogen bond interactions and the nitro groups in electrostatic forces of attraction enhanced the docking scores of these analogues.

Fig. 4. 2D and 3D images of compounds 7, 9, 21 and 23 with 2VF5 protein.

Fig. 4

Open in a new tab

3. Conclusions

In summary, we have developed a novel class of antioxidant, anti-inflammatory and antimicrobial agent with quinazolinone-hydrazones linked via Asp and Glu as connectors. In addition, molecular docking studies were performed on all the synthesized compounds. The correlation between molecular docking studies and biological assays suggested that compounds 6, 7, 11, 12, 20, 21, 25 and 26 with electron donating groups (OH, OCH3) exhibited stronger radical scavenging activity than ascorbic acid and gallic acid. Compounds 8, 9, 13, 14, 22, 23, 27 and 28 with electron withdrawing groups (Cl, NO2) demonstrated better in vitro anti-inflammatory activity than indomethacin and ibuprofen. The compounds with electron donating hydroxyl groups (7, 12, 21 and 26) and electron withdrawing nitro groups (9, 14, 23 and 28) exhibited potent antimicrobial properties among this series of compounds.

Conflicts of interest

There are no conflicts to declare.

Supplementary Material

RA-008-C8RA00531A-s001

Acknowledgments

The authors gratefully acknowledge the Department of Science and Technology (DST), New Delhi for awarding an Inspire Fellowship and the University Grant Commission (UGC), New Delhi for awarding a BSR Faculty Fellowship and UGC-Post Doctoral Fellowship (PDFSS). We also acknowledge DST-Purse and the computer science department for providing instrumentation facilities and docking facilities, respectively.

†

Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ra00531a

References

  1. Yao L. Evans J. A. Rzhetsky A. Trends Biotechnol. 2010;28:161–170. doi: 10.1016/j.tibtech.2010.01.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Terry H., Medicinal Chemistry: progress through innovation, Drug discovery world, 2006 [Google Scholar]
  3. Chandrika P. M. Yakaiah T. Gayatri G. Pranay K. K. Narsaiah B. Murthy U. S. N. Rao A. R. R. Eur. J. Med. Chem. 2010;45:78–84. doi: 10.1016/j.ejmech.2009.09.027. [DOI] [PubMed] [Google Scholar]
  4. Rajan S. G. Hardik M. T. Tony G. Jill W. Donna R. Vasudevan S. Kamala K. V. Eur. J. Med. Chem. 2009;44:2184–2189. doi: 10.1016/j.ejmech.2008.10.031. [DOI] [PubMed] [Google Scholar]
  5. Zhu S. Wang J. Chandrashekar G. Smith E. Liu X. Zhang Y. Eur. J. Med. Chem. 2010;45:3864–3869. doi: 10.1016/j.ejmech.2010.05.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Maria Z. Silvana G. Nicola M. Giuseppe Z. Frank S. M. Guido F. Giovambattista D. S. Carlo D. M. Bioorg. Med. Chem. Lett. 2003;13:4427–4430. doi: 10.1016/j.bmcl.2003.09.032. [DOI] [PubMed] [Google Scholar]
  7. Alagarsamy V. Pathak U. S. Bioorg. Med. Chem. 2007;15:3457–3462. doi: 10.1016/j.bmc.2007.03.007. [DOI] [PubMed] [Google Scholar]
  8. Malamas M. S. Millen J. J. Med. Chem. 1991;34:1492–1503. doi: 10.1021/jm00108a038. [DOI] [PubMed] [Google Scholar]
  9. Giuseppe G. Gianfranco B. Loredana V. Ferdinando M. M. et al. . Bioorg. Med. Chem. Lett. 2014;24:462–466. doi: 10.1016/j.bmcl.2013.12.048. [DOI] [PubMed] [Google Scholar]
  10. Abdulrahman M. A. Sami G. A. Hassan A. E. Alaa A. Adel S. E. Hamad A. A. Hussein I. E. Eur. J. Med. Chem. 2009;44:2379–2391. doi: 10.1016/j.ejmech.2008.09.015. [DOI] [PubMed] [Google Scholar]
  11. Natvar A. S. Ritu B. D. Rajesh K. P. Jayanti P. P. Bharat C. D. J. Saudi Chem. Soc. 2016;20:S29–S37. doi: 10.1016/j.jscs.2012.07.020. [DOI] [Google Scholar]
  12. Kandpal B. Meshram J. Mohanram I. Shaikh A. Med. Chem. Res. 2015;24:1419–1426. doi: 10.1007/s00044-014-1226-3. [DOI] [Google Scholar]
  13. Gao X. Cai X. Yan K. Song B. Gao L. Chen Z. Molecules. 2007;12:2621–2642. doi: 10.3390/12122621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Alagarsamy V. Shankar D. Solomon V. R. Sheorey R. V. Parthiban P. Acta Pharm. 2009;59:75–88. doi: 10.1111/j.1600-0773.1986.tb02712.x. [DOI] [PubMed] [Google Scholar]
  15. Gursoy A. Karali N. Eur. J. Med. Chem. 2003;38:633–643. doi: 10.1016/S0223-5234(03)00085-0. [DOI] [PubMed] [Google Scholar]
  16. Garrett A. R. Weagel E. G. Martinez A. D. Heaton M. Robison R. A. O’Neill K. L. Food Chem. 2014;158:490–496. doi: 10.1016/j.foodchem.2014.02.102. [DOI] [PubMed] [Google Scholar]
  17. Renck D. Machado P. Souto A. A. Rosado L. A. Erig T. Campos M. M. Farias C. B. Roesler R. Timmers L. F. S. M. de Souza O. N. Santos D. S. Basso L. A. J. Med. Chem. 2013;56:8892–8902. doi: 10.1021/jm401389u. [DOI] [PubMed] [Google Scholar]
  18. Kumara H. K. Gowda D. C. Int. J. Pept. Res. Ther. 2017;23:259–267. doi: 10.1007/s10989-016-9557-1. [DOI] [Google Scholar]
  19. Kumara H. K. Vardhan D. M. S. Kumar J. S. Gowda D. C. Anti-Inflammatory Anti-Allergy Agents Med. Chem. 2017;16:123–133. doi: 10.2174/1871523016666170817102243. [DOI] [PubMed] [Google Scholar]
  20. Suresha G. P. Suhas R. Kapfo W. Gowda D. C. Eur. J. Med. Chem. 2011;46:2530–2540. doi: 10.1016/j.ejmech.2011.03.041. [DOI] [PubMed] [Google Scholar]
  21. Suhas R. Chandrashekar S. Anil S. M. Gowda D. C. Protein Pept. Lett. 2013;20:146–155. doi: 10.2174/092986613804725235. [DOI] [PubMed] [Google Scholar]
  22. Rakesh K. P. Manukumar H. M. Gowda D. C. Bioorg. Med. Chem. Lett. 2015;25:1072–1077. doi: 10.1016/j.bmcl.2015.01.010. [DOI] [PubMed] [Google Scholar]
  23. Suhas R. Chandrashekar S. Gowda D. C. Eur. J. Med. Chem. 2011;46:704–711. doi: 10.1016/j.ejmech.2010.12.005. [DOI] [PubMed] [Google Scholar]
  24. Shantharam C. S. Vardhan D. M. S. Suhas R. Sridhara M. B. Gowda D. C. Eur. J. Med. Chem. 2013;60:325–332. doi: 10.1016/j.ejmech.2012.12.029. [DOI] [PubMed] [Google Scholar]
  25. Sharma A. Suhas R. Chandana K. V. Banu S. H. Gowda D. C. Bioorg. Med. Chem. Lett. 2013;23:4096–4098. doi: 10.1016/j.bmcl.2013.05.043. [DOI] [PubMed] [Google Scholar]
  26. Santhosh B. M. Narasimha P. A. J. Org. Chem. 2001;66:9038–9040. doi: 10.1021/jo010727l. [DOI] [PubMed] [Google Scholar]
  27. Wohlrab A. Lamer R. VanNieuwenhze M. S. J. Am. Chem. Soc. 2007;129:4175–4177. doi: 10.1021/ja068455x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Fournier J. Bruneau C. Dixneuf H. Lécolier S. J. Org. Chem. 1991;56:4456–4458. doi: 10.1021/jo00014a024. [DOI] [Google Scholar]
  29. Blois L. Nature. 1958;181:1199–1200. doi: 10.1038/1811199a0. [DOI] [Google Scholar]
  30. Fogliano V. Verde V. Randazzo G. Ritieni A. J. Agric. Food Chem. 1999;47:1035–1040. doi: 10.1021/jf980496s. [DOI] [PubMed] [Google Scholar]
  31. Glucin I. Innovative Food Sci. Emerging Technol. 2010;11:210–218. doi: 10.1016/j.ifset.2009.07.002. [DOI] [Google Scholar]
  32. Re R. Pellegrini N. Proteggente A. Pannala A. Yang M. Rice-Evan C. Free Radical Biol. Med. 1999;26:1231–1237. doi: 10.1016/S0891-5849(98)00315-3. [DOI] [PubMed] [Google Scholar]
  33. Rakesh K. P. Suhas R. Manukumar H. M. Chandan S. Gowda D. C. Eur. J. Chem. 2015;6:254–260. doi: 10.5155/eurjchem.6.3.254-260.1233. [DOI] [Google Scholar]
  34. Khan K. M. Rani M. Ambreen N. Ejaz A. Perveen S. Haider S. M. Choudhary M. I. Voelter W. Lett. Drug Des. Discovery. 2012;9:135–139. doi: 10.2174/157018012799079798. [DOI] [Google Scholar]
  35. Hao X. Han Z. Li Y. Li C. Wang X. Zhang X. Yang Q. Ma B. Zhu C. Bioorg. Med. Chem. Lett. 2017;27:887–892. doi: 10.1016/j.bmcl.2017.01.006. [DOI] [PubMed] [Google Scholar]
  36. Sahu P. K. Sahu P. K. Sahu P. L. Agarwal D. D. Bioorg. Med. Chem. Lett. 2016;26:1342–1347. doi: 10.1016/j.bmcl.2015.12.013. [DOI] [PubMed] [Google Scholar]
  37. Sushama K. Sunil T. Manoj D. Jaiprakash S. Rajendra P. Bioorg. Med. Chem. Lett. 2017;27:3891–3896. doi: 10.1016/j.bmcl.2017.06.043. [DOI] [PubMed] [Google Scholar]
  38. Shinde U. A. Phadke A. S. Nair A. M. Mungantiwar A. A. Dikshit V. J. Saraf M. N. Fitoterapia. 1999;70:251–257. doi: 10.1016/S0367-326X(99)00030-1. [DOI] [Google Scholar]
  39. Ashish P. K. Girish D. H. Rajesh H. T. Atish H. R. Satish S. B. Vandana M. K. Bioorg. Med. Chem. Lett. 2012;22:3445–3448. doi: 10.1016/j.bmcl.2012.03.092. [DOI] [PubMed] [Google Scholar]
  40. Perez C. Paul M. Bazerque P. Acta Biol. Med. Exp. 1990;56:113–115. [Google Scholar]
  41. Singh I. Singh V. P. Phytomorphology. 2000;50:151–157. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

RA-008-C8RA00531A-s001
RA-008-C8RA00531A-s001.pdf (2MB, pdf)

Articles from RSC Advances are provided here courtesy of Royal Society of Chemistry

RESOURCES